Current Development of Anti-Cancer Drug S-1.

about

Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial.5-Chloro-2,4-dihydroxypyridine, CDHP, prevents lung metastasis of basal-like breast cancer cells by reducing nascent adhesion formation.

P2860

Q45384459-EF18FB2B-9EDB-47D5-B3D0-0F5B2AD92D2A Q47719860-B307C395-8782-469E-8895-4D193E7C59D7

P2860

Current Development of Anti-Cancer Drug S-1.

Item

http://www.wikidata.org/entity/Q37543342

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Current Development of Anti-Cancer Drug S-1.

@en

Current Development of Anti-Cancer Drug S-1.

@nl

type

Item

label

Current Development of Anti-Cancer Drug S-1.

@en

Current Development of Anti-Cancer Drug S-1.

@nl

prefLabel

Current Development of Anti-Cancer Drug S-1.

@en

Current Development of Anti-Cancer Drug S-1.

@nl

P1476

Current Development of Anti-Cancer Drug S-1

@en

P2093

Anil Giri

http://www.w3.org/2001/XMLSchema#string

K C Pramod

http://www.w3.org/2001/XMLSchema#string

Pratima Chhetri

http://www.w3.org/2001/XMLSchema#string

Sujana Shakya

http://www.w3.org/2001/XMLSchema#string

Suraj Shakya

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver

Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.

Phase II study of combination chemotherapy with S-1 and weekly cisplatin in patients with previously untreated advanced non-small cell lung cancer.

Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis

Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies.

The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.

Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.

P304

XE01-XE05

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7860/JCDR/2016/19345.8776

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Binaya Sapkota

P577

2016-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28050491

http://www.w3.org/2001/XMLSchema#string

P932

5198444

http://www.w3.org/2001/XMLSchema#string

Current Development of Anti-Cancer Drug S-1.

about

P2860

P2860

Current Development of Anti-Cancer Drug S-1.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932